Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema

BACKGROUND: Diabetic macular edema (DME) can be treated with different alternatives, among them Dexamethasone intravitreal implant 0.7 mg (DEX 0.7) has demonstrated that may improve both central macular thickness (CMT) and best corrected visual acuity (BCVA). This study aimed to evaluate the effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro-Navarro, Verónica, Cervera-Taulet, Enrique, Navarro-Palop, Catalina, Monferrer-Adsuara, Clara, Hernández-Bel, Laura, Montero-Hernández, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330395/
https://www.ncbi.nlm.nih.gov/pubmed/30634940
http://dx.doi.org/10.1186/s12886-018-1022-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6330395/
https://www.ncbi.nlm.nih.gov/pubmed/30634940
http://dx.doi.org/10.1186/s12886-018-1022-9

Ejemplares similares